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ABSTRACT 
Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects approximately 1% 
of the population worldwide. Despite being rather common, the etiopathology of RA remains 
unclear. Approximately two-thirds of patients have antibodies to citrullinated proteins 
(ACPAs), generally detected using the 2nd generation cyclic citrullinated peptide (CCP2) 
ELISA. A wealth of evidence implicates ACPA in the etiology of RA: the major risk factors - 
a group of HLA-DRB1 alleles referred to as the shared epitope (SE), and smoking - have 
been described to associate primarily with the ACPA-positive subset of RA. Moreover, 
ACPAs can be detected years before clinical onset, and their presence are highly predictive of 
progression to RA. However, the mechanism by which ACPAs might contribute to disease, 
as well as the definitive in vivo target, is not understood. The aim of this thesis was therefore 
to better characterize the ACPA response in RA, in terms of antigen specificity, association 
with genetic and environmental risk factors, cross-reactivity with carbamylated antigens, 
presence in CCP2-negative RA, and finally the antigen specificity and functional 
characteristics of ACPA-positive B cells.  
Through studies using affinity purified anti-CCP2 IgG, we could demonstrate that the CCP2 
ELISA directly captures the ACPA response, and that ACPA purified in this manner bound a 
variety of citrullinated peptide epitopes and exhibited binding to RA synovial tissue and 
immune cells (Study I). We also discovered that purified ACPA could bind both 
carbamylated and citrullinated proteins, and peptide absorption experiments confirmed 
extensive cross-reactivity between ACPA and anti-carbamylated protein (CarP) antibodies in 
the context of the candidate autoantigen α-enolase, casting doubt on the specificity of the 
anti-CarP response, which we posit may be cross-reactive ACPA (Study II). By screening 
2,836 serum samples from the population-based case-control cohort EIRA on an autoantigen 
multiplex array, we then showed that “seronegative” RA is not truly a seronegative disease 
subset. Autoantibodies - including ACPA and rheumatoid factor (RF) - were present in a 
substantial proportion, and this subset resembled seropositive RA in terms of associations 
with risk factors (Study III). This study highlights the need for new biomarkers, better 
classification of seronegative RA, and more sensitive clinical tests for seropositive RA. 
Finally, we utilized a method of B cell immortalization to derive ACPA-producing B cell 
clones from RA synovial fluid that retained surface immunoglobulin expression. We 
successfully generated a CEP-1-positive B cell clone from a SE-positive RA patient, and 
visualized surface binding to citrullinated (but not native) protein (Study IV). This pilot study 
lays the ground for in-depth investigation of the characteristics of the ACPA lymphocyte 
population, specifically in regards to HLA-DRB1 SE-mediated antigen presentation. 
It is my hope that the data presented in this thesis can provide a basis for future studies into 
the putative specificity and mechanism of the ACPA response, in order to elucidate disease 
processes in RA and ultimately improve the diagnosis and treatment of the disease.  
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1 INTRODUCTION 
 
1.1 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a severe autoimmune disease characterized by chronic 
inflammation of the joints. RA is endemic in almost all human populations, affecting 
approximately 0.5-1% of the population worldwide (1). RA affects primarily women, with a 
roughly 3:1 ratio of women to men (2), and typically occurs later in life (3). In addition to 
chronic pain, fatigue and possible disability, RA patients also exhibit increased morbidity and 
mortality, primarily from cardiovascular disease (CVD) (4). 
The primary tissue affected by RA is the synovium of the joint. In healthy individuals, 
the synovial membrane is comprised of a thin cell layer of synovial fibroblasts and 
macrophages, which maintain homeostasis in the joint. In RA, synovial inflammation leads to 
the development of a thick cellular layer called the pannus, which begins to grow over the 
articular surface. Synoviocytes and infiltrating immune cells, most notably neutrophils, 
macrophages, and T- and B-lymphocytes, fill the inflamed joint with pro-inflammatory 
cytokines, chemokines, prostaglandins and cartilage-degrading enzymes such as 
metalloproteinases (5), destroying cartilage as well as driving an inappropriate activation of 
osteoclasts to resorb bone, ultimately leading to permanent destruction of the joint (6).  
RA typically presents as polyarthritis, and is currently diagnosed according to the new 
unified ACR / EULAR criteria for RA, established in 2010 (7) (Table 1). The 2010 ACR / 
EULAR criteria additionally classify patients as seropositive or seronegative, based on the 
presence/absence of specific autoantibodies: rheumatoid factor (RF) directed against the 
constant region of immunoglobulin G, and anti-citrullinated protein antibodies (ACPA) 
directed against citrullinated proteins.  
Upon diagnosis, treatment is initiated with anti-inflammatory therapies such as 
glucocorticoids to quickly reduce pain and inflammation, coupled with administration of 
disease-modifying antirheumatic drugs (DMARDs) and/or biologicals aimed at long-term 
disease control (8). Aggressive treatment early in diagnosis can delay or prevent many of the 
more serious manifestations of the disease (9). 
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Table 1      The 2010 ACR/EULAR classification criteria for RA 
 
 Score* 
Symptom Duration  
< 6 weeks 0 
≥ 6 weeks 1 
  
Joint Distribution  
1 large joint 0 
2-10 large joints 1 
1-3 small joints (with or without involvement of large joints) 2 
4-10 small joints (with or without involvement of large joints) 3 
> 10 joints (at least 1 small joint) 5 
  
Serology  
RF- and ACPA- 0 
Low RF+ or low ACPA+ 1 
High RF+ or high ACPA+ 2 
  
Acute Phase Reactants  
Normal CRP and normal ESR 0 
Abnormal CRP or ESR 1 
  
* Scores of 6 or greater are classified as having RA. CRP = C-reactive protein; ESR = 
erythrocyte sedimentation rate. Adapted from Aletaha et al (10). 
 
Methotrexate (MTX) remains the standard first-line DMARD in RA (11); however, 
during the past few decades, a variety of biological DMARDs have entered the clinic, 
primarily targeting inflammatory cytokines. The most common of these have been 
biologicals inhibiting anti-tumor necrosis factor (TNF), including adalimumab, certolizumab, 
etanercept, golimumab and infliximab. In patients refractory to anti-TNF, B-cell depletion via 
the anti-CD20 antibody rituximab can be effective (12). Other biologicals include anakinra, 
the IL-1 receptor antagonist, the CTLA4-Ig fusion protein abatacept, which targets T cells, 
and the anti-IL-6 receptor antibody tocilizumab. The high cost of biologicals precludes their 
use as first-line DMARDs in many countries; they can also become immunogenic, leading to 
a loss of efficacy over time (13). Furthermore, many patients do not respond satisfactorily to 
biologicals due to side effects or for unknown reasons. In addition, even if inflammation 
subsides, many patients still experience pain and fatigue. 
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The development of novel therapies requires a greater understanding of the 
pathological mechanisms underlying RA, which yet remain unclear. Elucidating these 
mechanisms could provide better tools for earlier diagnosis, individual tailoring of therapies, 
and potentially make possible the development of antigen-specific tolerizing therapies (14) to 
treat or even prevent the disease in pre-disposed individuals.  
 
1.2 RISK FACTORS FOR RA: CLUES TO ETIOPATHOLOGY? 
Risk for developing RA has a definitive genetic component, with a concordance rate of 
7-15% in monozygotic twins (15,16). The major genetic risk factors for RA are associated 
with adaptive immunity. Chief among these are certain alleles of the gene HLA-DRB1, 
coding for the beta chain of major immunohistocompability complex type II (MHC II).  
 
1.2.1 Shared epitope 
A group of HLA-DRB1 RA risk alleles were found to share the same 5-amino acid 
sequence motif in the third hyper variable region in the peptide-binding groove, and are 
therefore collectively referred to as shared epitope (SE) (17). These alleles were later found to 
share a common arrangement of specific amino acids in certain positions in the peptide 
binding groove of MHC-II (18). The SE hypothesis proposes that these specific MHC II 
molecules may efficiently present specific peptides to autoreactive T cells. Conversely, other 
DRB1 alleles have been found to have a protective effect in RA (19). Importantly, SE is only 
a risk factor for ACPA-positive disease (20). 
 
1.2.2 PTPN22 polymorphism 
In addition to SE, polymorphism in protein tyrosine phosphatase nonreceptor 22 
(PTPN22), a protein tyrosine phosphatase expressed in lymphoid cells, have been associated 
with increased risk for autoimmunity, including RA (21). PTPN22 acts as a negative 
regulator of lymphocyte activity, and the common C1858T (rs2476601) allelic variant, 
resulting from a non-synonymous Arg620Trp single nucleotide mutation, is thought to 
contribute to autoimmunity by increasing survival in autoreactive lymphocytes (22). PTPN22 
C1858T is understood to be a shared risk factor for autoimmunity (23), and healthy carriers 
of the risk allele have been shown to have more autoreactive B cells in the periphery 
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compared to non-carriers. Interestingly, a gene-gene interaction between SE and PTPN22 has 
been described to increase RA risk progressively, and while PTPN22 associates with both 
seropositive and seronegative RA, the gene-gene interaction is only present in the 
seropositive subset (24). 
 
1.2.3 Other genetic risk factors 
In light of the ACPA response in RA, it is interesting that polymorphisms in the gene 
encoding the citrullinating enzyme peptidyl-arginine deiminase 4 (PAD4) have been 
associated with RA, primarily in Asian populations (25,26). A wide range of other risk genes 
have also been identified in RA, a large number of which govern immune function (27). Most 
of these genetic risk factors seem to associate mainly with ACPA-positive RA. 
 
1.3 ENVIRONMENTAL RISK FACTORS 
In addition to genetic risk factors, environmental exposures, hormones, and lifestyle 
factors contribute the development of RA, with smoking being the most established non-
genetic risk factor for RA (28). Interestingly, a gene-environment interaction between SE and 
smoking exists in seropositive RA (29). 
 
1.3.1 Smoking 
An epidemiological association between smoking and RA was first described in 1987 
(28) and ten years later explicitly demonstrated in a twin cohort where participants were 
discordant for RA (30). The association of smoking with RA has since been confirmed in a 
large number of studies (31). Similarly, silica exposure (32) and textile dust exposure (33) 
have also been identified as risk factors for RA, collectively implicating inflammation in the 
lung in the etiology of the disease. Interestingly, it has been shown that chronic inflammation 
in the lungs of smokers as well as chronic obstructive pulmonary disease (COPD) cause 
increased protein citrullination (34,35), thereby increasing the exposure of ACPA targets to 
the immune system; RA-related autoantibodies have also been found (albeit at low levels) in 
several inflammatory lung diseases (36), and in bronchoalveolar lavage of RA patients (37). 
  5 
These studies pinpoint the lung as a possible site for initiating the ACPA response. Of note, 
the lungs are one of the most commons sites of extra-articular manifestations in RA (38). 
 
1.3.2 Microbial exposure 
A microbial basis for RA has long been hypothesized, with Epstein-Barr virus, 
parvovirus and cytomegalovirus infection historically implicated (39), though there is still no 
consensus regarding these viruses due to contradictory data (40). An association between 
periodontitis and RA has also long been discussed, with the epidemiological association 
between these two diseases being recently confirmed in a systemic meta analysis (41). It has 
been proposed that the link between RA and periodontitis could be accounted for by the oral 
bacteria Porphyromonas gingivalis (P.g), a major causative agent in the development of 
chronic periodontitis, that intriguingly expresses an enzyme capable of protein citrullination 
(42,43). A number of studies have shown increased levels of antibodies against P.g. in RA 
compared to healthy controls, especially in ACPA-positive RA (44). Moreover, an interaction 
between elevated anti-P.g. antibody levels and HLA-DRB1 SE, as well as cigarette smoking, 
has been described in the ACPA-positive subset of RA (45). More recently, Aggregatibacter 
actinomycetemcomitans (Aa), a Gram-negative bacterium linked to the development of 
aggressive periodontitis, has been demonstrated to induce hypercitrullination in neutrophils 
via a membranolytic pathway (46). Furthermore, association between SE and the presence of 
ACPAs and RF was found only in RA patients possessing anti-Aa antibodies, suggesting a 
causal link between exposure to AA and the development of ACPA-positive RA. Notably, 
citrullinated proteins are present in inflamed gingival tissue (43,47), and ACPA have been 
reported in non-RA patients with chronic periodontitis (48,49).      
 
1.4 ROLE OF AUTOANTIBODIES IN RA: BIOMARKERS AND POTENTIAL 
PATHOLOGICAL AGENTS 
Originally described in the 1930s, rheumatoid factor (RF), autoantibodies to the Fc 
portion of IgG, is one of the earliest known biomarkers for RA (50). While IgM RF is the 
most common isotype and most often measured clinically, IgG and IgA forms of RF also 
exist. IgA RF in particular is associated with smoking in RA patients (36,51), implicating 
mucosal immunity in the pathogenesis of the disease. Around two-thirds of RA patients are 
RF-positive, and RF-positive disease has been associated with a more severe disease course 
(52). While RF positivity has long been used to diagnose RA, its utility as a biomarker is 
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handicapped by its low sensitivity: among other instances, RF is found in other autoimmune 
diseases (53), B-cell lymphomas, as well as in systemically healthy individuals during 
infections  (54). RF would therefore seem to be more associated with states of immune 
activation than RA per se. 
In addition to RF, a variety of other autoantibodies have been historically associated 
with RA. Of these, the most important were antibodies binding to keratin (anti-keratin 
antibodies, or AKA), and the so called anti-perinuclear factor (APF) (55), later identified as 
antibodies to filaggrin, a keratin-binding structural protein (56). As filaggrin is not expressed 
in the joint, further research into the true antigenic target of these autoantibodies eventually 
led to the historic discovery that their real target was in fact citrullinated proteins (57,58). 
These autoantibodies are now collectively referred to as anti-citrullinated protein antibodies, 
or ACPAs.  The cyclic citrullinated peptide (CCP) test, which was the first commercially 
available assay for ACPA positivity, was based on cyclic citrullinated filaggrin-derived 
peptides (59); however, the second generation CCP test (CCP2) currently used in many 
clinics uses a combination of synthetic citrullinated peptide epitopes derived from a phage 
display library to provide an optimal combination of sensitivity and specificity for diagnosing 
RA (60). Importantly, the CCP2 peptide does not contain sequences derived from human 
proteins. 
The presence of ACPAs detected in this manner is highly specific for RA (i.e. 98%) 
(61), and around two-thirds of RA patients are positive for ACPAs. Together with RF, ACPA 
positivity is now a part of the current ACR EULAR criteria for RA (7), and the presence of 
ACPA and/or RF defines the seropositive subset of the disease. As with RF (62), ACPAs can 
be present for many years before joint symptoms develop, and are predictive of progression 
to RA (63,64), as well as a more destructive disease course, suggesting a direct pathogenic 
involvement. Crucially, it is now understood that SE and smoking are associated mainly with 
the development of ACPA-positive disease (65). However, given the extensive co-occurrence 
of ACPA and RF, and the strong gene-environment interaction between SE and smoking, it 
becomes difficult to elucidate the mechanistic relationship between ACPA and RF and 
SE/smoking in the etiopathogenesis of seropositive disease. Still, in recent years, focus has 
moved from RF to ACPA, when trying to understand the pathways underpinning RA. 
 
 
  7 
1.5 CITRULLINATION IN HEALTH AND DISEASE 
Whereas L-citrulline is an ubiquitous non-coded amino acid generated as an 
intermediate in the urea cycle, peptidyl citrulline is found exclusively as a post-translational 
modification (PTM) arising from deimination of arginine residues by a class of calcium-
dependent enzymes, the peptidyl arginine deiminases, or PADs. Five different PAD isoforms 
have been described in humans, with differences in tissue expression, substrate specificity 
and subcellular localization (66). Of these, only PAD2 and PAD4 have been identified in the 
synovium; their increased expression has been correlated with the degree of inflammation in 
synovitis (67,68).  
Physiological citrullination is widespread: for example, the production of functional 
myelin in the central nervous system requires citrullination, and citrullination takes place 
during the formation of cornified layer of the epidermis (69). While upregulation of 
citrullinated proteins was at first posited to be a specific feature of rheumatic synovitis, 
citrullination has also been observed to be increased in non-RA synovitides (70). It has since 
been observed that inflammation-related upregulation of citrullination is not specific to joints, 
but seems to be a general feature of inflammation (71). For instance, increased protein 
citrullination has been described in the lungs of smokers (34,35), in the gingival tissue of 
periodontitis patients (47), in inflamed tonsils (71), in the brain of patients with Alzheimer’s 
disease (72) and multiple sclerosis (73), and in the muscles of myositis patients (29). 
Citrullinated proteins are also present in atherosclerotic plaques, providing a potential 
mechanistic link to cardiovascular disease in ACPA-positive RA (74).  
The link between increased protein citrullination and inflammation is not fully 
understood, but could be related to increased necrotic cell death. PAD activity is dependent 
on high Ca2+ concentrations, which are normally not present intracellularly, but when the cell 
membrane integrity is lost - as a result of terminal differentiation of cells or necrosis - the 
intracellular Ca2+ concentration is increased, and PAD can become activated. During 
necrosis, PAD could also be released to the extracellular space, with the potential to 
citrullinate extracellular proteins (75). 
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1.6 CITRULLINATED CANDIDATE AUTOANTIGENS 
While first described as binding to citrullinated fibrinogen present in the synovium 
(76), the “true” antigenic target of ACPAs is unknown: ACPAs have been demonstrated to 
bind to a variety of candidate citrullinated autoantigens also present in the synovium: 
vimentin (77), collagen type II (78), a-enolase (79) and more recently histones (80,81).  
 
1.6.1 Fibrinogen 
Fibrinogen is a hexameric plasma glycoprotein central to coagulation. As the inactive 
precursor of fibrin, fibrinogen is cleaved by the protease thrombin to fibrin monomers, which 
then polymerize to form a clot. Antibodies to citrullinated fibrinogen epitopes are found in 
approximately 50-60% of RA patients (82). Deposition of fibrin in the synovium is a feature 
of early RA synovitis, and has been posited to be a possible mechanism for the initiation of 
pannus formation (83).  
 
1.6.2 Collagen type II 
Collagen type II is a major constituent of hyaline cartilage, and is therefore a logical 
candidate antigen for RA. Immunization with collagen type II in rodents leads to the 
development of autoimmune arthritis resembling RA (collagen-induced arthritis, or CIA) 
(84), a widely-used animal model dependent on activation of both T (85) and B (86) 
lymphocytes. Antibodies to citrullinated collagen type II are found in up to 40% of RA 
patients (78). 
 
1.6.3 Vimentin 
Vimentin is a ubiquitously expressed component of intermediate filament, a major 
constituent of the cytoskeleton in eukaryotic cells. Antibodies to a mutated citrullinated 
isoform of vimentin (MCV) are found in approximately two-thirds of RA patients, and are 
used clinically as an alternative to the anti-CCP2 test, with comparable sensitivity and 
specificity (87), and potentially superior to CCP2 as a marker for joint destruction (88). 
While primarily an intracellular protein, one potential source of extracellular vimentin could 
be secretion by activated macrophages (89), which could then be citrullinated in an 
inflammatory microenvironment.  
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1.6.4 a-Enolase 
a-enolase, or non-neuronal enolase, is an isoform of enolase, an ubiquitously expressed 
glycolytic enzyme. Antibodies to the immunodominant citrullinated peptide epitope CEP-1 
are found in approximately 40% of RA patients (90). a-enolase is expressed in the cytoplasm 
and in the nucleus, and on the surface where it may function as a plasminogen receptor, 
which is upregulated during inflammation (91). Increased expression of a-enolase has for 
example been demonstrated in RA synovial fluid and -synovial tissue (79,92). Additionally, 
isoforms of enolase with a high sequence similarity to human a-enolase are expressed by 
several pathogenic bacteria, including Porphyromonas gingivalis. Anti-CEP-1 antibodies 
purified from RA sera bind citrullinated P.g. enolase, suggesting that molecular mimicry may 
play a role in the generation of the ACPA response in RA.  
 
1.6.5 Histones 
Large numbers of activated neutrophils infiltrate the RA synovial fluid and pannus 
(93), where they comprise a source of inflammatory signals and cause tissue damage through 
the generation of reactive oxygen species (ROS). They may also contribute specifically to the 
ACPA response through NETosis, a mechanism normally used by neutrophils to kill 
extracellular bacteria, in which activated neutrophils release their chromatin extracellularly, 
creating a sticky mesh of chromatin complexed with cytotoxic granules called neutrophil 
extracellular traps (NETs) to snare and kill pathogens (94). Hypercitrullination of histones by 
PAD4 is understood to be crucial to this process (95). NETosis is upregulated in RA and 
correlates with ACPA status (80), and ACPAs have been shown to specifically bind to 
citrullinated histones (81). 
 
1.7 AN ETIOLOGICAL HYPOTHESIS FOR THE DEVELOPMENT OF ACPA-
POSITIVE RA  
Based on the epidemiological association between RA and smoking, and between RA 
and periodontal disease, and the observation of increased PAD activity/protein citrullination 
in inflamed lungs and gingival tissue, it has been suggested that ACPA-positive RA may be 
triggered at mucosal sites, and a potential etiological model has emerged for the development 
of ACPA-positive RA (Figure 1, reviewed in (96)).  
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Figure 1: An etiological model for the etiology of ACPA-positive RA. Genetic risk factors 
(SE and PTPN22) and environmental insults (smoking, particulates, microbes) interact to 
cause a break in immunity towards citrullinated self-antigens in mucosal tissue, leading to 
autoimmunity and the production of ACPAs prior to joint pathology, which likely requires a 
second “hit” to initiate RA. Reproduced with permission from Nature Reviews 
Rheumatology (97). 
 
First, environmental factors such as smoking or infections lead to increased protein 
citrullination as a result of inflammation and subsequent upregulation of PAD activity. In the 
presence of danger signals (such as toxic components of cigarette smoke and/or bacterial 
DNA/LPS etc.), a break in tolerance to citrullinated protein(s) may occur, especially in 
genetically predisposed individuals – most importantly through SE-restricted presentation of 
citrullinated peptides on MHC II (29) to pathogenic T cells, and through increased resistance 
of autoreactive lymphocytes to induction of tolerance in the presence of PTPN22 risk alleles. 
Activated T cells subsequently help B cells to produce pro-inflammatory cytokines and high 
affinity ACPA, through clonal selection and antigen-driven affinity maturation.  
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Since ACPAs can be present for many years prior to the development of synovitis, a 
“second hit” is likely required in these pre-disposed individuals, in which an initiating event 
gives rise to inflammation in the joint, causing an upregulation of citrullination and activation 
and broadening of the ACPA response (98). Ultimately this results in a vicious circle of cell 
death, PAD activation, citrullination, ACPA production, immune complex formation, Fc 
receptor and/or complement engagement, and the activation of osteoclasts leading to 
increased bone resorption (99), eventually causing chronic inflammation and RA. 
The mechanism through which ACPAs exert these effects is not understood, but a 
wealth of experimental evidence implicates that they may act in a variety of ways to 
contribute to disease (100). For example, immune complexes containing citrullinated proteins 
and ACPA can active immune cells through Fc-receptor engagement (101), and are 
potentiated by RF (102). They might also function in an Fc-independent manner: the 
increased activation of osteoclasts by ACPAs has been demonstrated to occur through a 
chemokine-dependent mechanism (103), and a similar mechanism is thought to be 
responsible for pain behavior upon transfer of ACPAs to mice through activation of 
nocicecptors (104); low-avidity ACPA have also been demonstrated to be strong activators of 
complement (105).  
 
1.8 ANTIBODIES TO CARBAMYLATED PROTEINS 
Recently, antibodies to carbamylated proteins were identified in RA, denoted “anti-
CarP antibodies” (106). This confirmed earlier studies which described similar autoimmune 
reactions in animal models of arthritis (107,108). Carbamylation is a non-enzyme-dependent 
process in which the primary amines in the side chains of lysine residues react with cyanate 
ions to form homocitrulline, which is chemically similar to citrulline but contains an 
additional methyl group (Figure 2). Carbamylation is upregulated in inflammation, primarily 
through the production of cyanate by neutrophil myeloperoxidase; notably, increased plasma 
cyanate is also found in smokers (109).  
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Figure 2: Peptidyl citrulline (left) and peptidyl homocitrulline (right). Citrulline is a 
noncharged amino acid resulting from deimination of arginine residues; homocitrulline is a 
noncharged amino acid resulting from carbamylation of lysine residues. 
 
Anti-CarP antibodies share many similarities to ACPAs: they are specific for RA 
(though they have also been described at low frequencies in primary Sjögren’s disease (110)), 
and they are present prior to diagnosis, in which case they are also predictive for the 
development of RA (111). It has since been shown that the most commonly used in vitro 
method for the detection of peptidyl citrulline, the Senshu method (112), does not 
discriminate between homocitrulline and citrulline (113). Additionally, work with 
carbamylated fibrinogen has revealed cross-reactivity with ACPAs (114); however, several 
animal models of RA have been described to develop anti-CarP antibodies without ACPA 
(115). Importantly, there is no association between the presence of anti-CarP antibodies and 
specific risk factors for RA, such as SE alleles or smoking (116). In addition to carbamylated 
fibrinogen, anti-CarP antibodies have been demonstrated to target carbamylated vimentin 
(117,118). Antibodies to acetylated vimentin have also been described in RA (119).  
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1.9 THE ROLE OF B CELLS IN RA  
RA synovitis is typically characterized by infiltration of both innate and adaptive 
immune cells, and the formation of ectopic lymphoid structures, resembling germinal centers, 
has been described in the joints during chronic inflammation (120). While T cells have 
historically been implicated as major drivers of disease (121), the relative increase in efficacy 
of the B cell-depleting therapy rituximab in seropositive RA versus seronegative RA suggests 
an important role for B cells in ACPA-positive RA (122-124). Importantly, rituximab 
treatment does not fully deplete B cells in RA synovium, which is posited to be a 
consequence of the abundance of pro-survival factors in the inflamed synovial 
microenvironment (125), and as rituximab is an anti-CD20 antibody, it does not target plasma 
cells or plasma blasts, which do not express CD20. ACPA production is thought to also occur 
locally in inflamed joints: ACPA IgG is enriched in the synovium (126,127), and single-cell 
cloning experiments have revealed that a large proportion of synovial B cells are ACPA-
positive (128).  
In addition to their function as antibody secreting cells, B cells could also initiate or 
drive disease through cytokine secretion as well as their ability to serve as specific antigen-
presenting cells (APCs). The latter is an intriguing possibility for initiation of disease in the 
absence of an obvious trigger, as even small amounts of citrullinated autoantigens could be 
efficiently captured and presented by ACPA-positive B cells, and could represent a direct 
mechanism for the contribution of SE alleles to RA pathogenesis.  
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2 AIMS 
The general aim of the work presented in this thesis was to investigate specific autoimmune 
reactions in RA, with focus on the ACPA response, in order to learn more about disease 
processes in RA. This was to be accomplished in the following projects: 
1. Purify and characterize the antigenic specificity of ACPAs (Study I) 
2. Investigate the specificity of ACPAs in regards to the recently described 
autoantibodies to carbamylated proteins (Study II) 
3. Analyze and characterize the CCP2-negative subset of RA in regards to ACPA fine-
specificities, RF isotypes and potential reactivity to non-RA-specific autoantigens, in 
relation to RA risk factors (Study III) 
4. Generate genetically reprogrammed B clones towards the investigation of the antigen 
specificity and functional charactersitics of ACPA-positive B cells (Study IV) 
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3 MATERIALS AND METHODS 
 
3.1 RA PATIENT MATERIAL 
In Studies I and II, anti-CCP2 IgG or anti-CEP-1 IgG were purified from non-paired 
synovial fluid (SF) and plasma samples collected with informed consent from RA patients 
attending the rheumatology clinic at Karolinska University Hospital, Stockholm, Sweden, 
from 2001 to 2011. SF was collected from patients requiring arthrocentesis. All patients 
fulfilled the ACR/EULAR criteria for RA and were selected on the basis of having high anti-
CCP2 antibody levels (>300 AU/mL), or a strong anti-CEP-1 antibody response. Samples 
were stored at −20°C (short term) or −80°C (long term) until processed. In Study I, ACPA 
binding to in vivo-generated antigens was investigated using SF mononuclear cells isolated 
from RA patients requiring arthrocentesis, and synovial tissues obtained from RA patients 
undergoing hip or knee joint replacement surgery, at the Karolinska University Hospital. In 
Study IV, immortalized B cells were generated from SF mononuclear cells, obtained from 
two patients requiring arthrocentesis: an ACPA-positive / HLA-DRB1-SE-positive RA 
patient, attending the Karolinska University Hospital, and an ACPA-negative / HLA-DRB1-
negative, non-RA control patient attending the Academic Medical Center (AMC), in 
Amsterdam, the Netherlands. 
 
3.2 EIRA 
In Studies II and III, a serum biobank from the Swedish population-based case-control study 
EIRA (Epidemiological Investigation of RA) was used to investigate antibody reactivities. 
The EIRA cohort consists of newly diagnosed RA cases and controls matched for age, sex 
and residential area. Blood samples were collected at the time of recruitment, and information 
on cigarette smoking (as well as other environmental exposures) was obtained via self-
reported questionnaire at baseline (129). Genotyping for the identification of SE alleles (i.e. 
HLA-DRB1*01 (except DRB1*0103), *04 and *10) and PTPN22 polymorphism (i.e. 
rs2476601) was performed on DNA from blood as previously described (24,65). Information 
on C-reactive protein (CRP) levels and disease activity score for 28 joints (DAS28) was 
obtained by linking EIRA with the Swedish rheumatology register, where clinical data is 
stored as part of standard care (130). Serum anti-CCP2 antibody levels were measured in 
house, as described below (20).  
 18 
For the studies included in this thesis, information on genetics, smoking habits, CRP 
levels, DAS28 and anti-CCP2 antibodies were retrieved from the EIRA database. 
 
3.3 ELISA 
In all studies, CCP2 positivity was determined in house using the anti-CCP2 IgG ELISA 
assay Immunoscan CCPlus® from Euro-Diagnostica AB, Malmö, Sweden, according to 
manufacturer instructions. Cutoff for positivity was 25 AU/mL. For detection of ACPA fine-
specificities, and anti-CarP antibodies, in house peptide and protein ELISAs were used as 
previously described (127,131). The use of a serum pool standard, made comparisons 
between different plates possible. Cutoff for positivity for each peptide ELISA was calculated 
on the basis of the 98th percentile in a group of 150 randomly selected EIRA controls.  
 
3.4 ISAC MULTIPLEX 
High-throughput investigation of antibody reactivities in the EIRA cohort was made possible 
through the use of the ImmunoCAP Immuno Solid-phase Allergen Chip (ISAC) peptide array 
system (Phadia AB, Uppsala, Sweden) containing antigens of interest, in Studies II, III and 
IV, as previously described (132,133). Antigens are spotted onto glass slides, which are then 
incubated with sample, washed to remove unbound antibody, and analyzed using a Cy3-
conjugated goat anti-human IgG (Jackson ImmunoResearch Laborities, Newmarket, UK). 
Antibody binding is then recorded as fluorescence intensity using a laser scanner, which is 
converted to normalized arbitrary units (AU/ml) after normalization against an internal 
control spot on each slide. Cutoff for positivity for each antigen was calculated as the 98th 
percentile using a group of 370 EIRA controls. 
 
3.5 ACPA PURIFICATION 
In Study I and Study II, polyclonal ACPA IgG was purified from ACPA-positive RA 
patient plasma and SF samples for use in in vitro experiments through affinity 
chromatography using the CCP2 peptide(s), kindly donated by Euro-Diagnostica AB. In 
brief, SF samples were centrifuged and treated with hyaluronidase to reduce viscosity, then 
proteins were precipitated and diluted in PBS; plasma samples were centrifuged and diluted 
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in PBS. Bulk IgG was isolated on Protein G coupled columns before CCP2 IgG was purified 
on CCP2 affinity columns. The CCP2-depleted flow through (FT) fraction was also 
preserved. In Study II, anti-CEP-1 IgG was isolated using a similar method: CEP-1 peptides, 
and the arginine-containing version REP-1, were directly coupled to NHS-Sepharose 
columns at 1 mg/ml. Protein G column purified IgG fractions from five CEP-1-positive 
serum samples were subsequently purified on the CEP-1 affinity column following pre-
absorption on the REP-1 column to eliminate any non-citrulline-specific antibodies. Also 
here, FT fractions were preserved. Purified anti-CCP2 IgG, anti-CEP-1 IgG and FT IgG were 
concentrated and buffer exchanged to PBS before aliquoted and stored at -20°C until further 
analyzed, or long-termed stored at -80°C. A total of three CCP2 pools were generated: one 
SF CCP2 pool from n=26 RA patients, and two plasma CCP2 pools from n=16 and n=38 RA 
patients, respectively. Purified anti-CEP-1 antibodies and FT fractions from the five CEP-1-
positive RA patients were not pooled, but kept separate. 
 
3.6 GENERATION OF POST-TRANSLATIONALLY MODIFIED PROTEINS 
In Studies I, II, and IV, citrullinated and carbamylated protein antigens were generated in 
house for use in in vitro experiments. Citrullination was performed by incubating proteins at a 
concentration of 1 mg/ml in PAD buffer (100 mM Tris, 10 mM CaCl2, 5 mM dithiothreitol 
(DTT), pH 7.6) with 2 U/mg protein of rabbit skeletal muscle PAD2 enzyme (Sigma, St. 
Louis, MO, USA) for 2 h at 37° C. The reaction was terminated by the addition of 20 mM 
ethylenediaminetetraacetic acid (EDTA), followed by thorough dialysis to calcium-free PBS. 
Carbamylation was performed by incubating proteins at a concentration of 1 mg/ml in PBS in 
the presence of 100 mM potassium cyanate overnight at 37°C, followed by thorough dialysis 
to calcium-free PBS. Successful citrullination and carbamylation were confirmed through 
mass spectrometry. 
 
3.7 IMMUNOBLOTTING 
In Study I and Study II, the purified ACPAs were analyzed for reactivity against modified 
proteins using Western Blot. Briefly, citrullinated, carbamylated or unmodified proteins were 
separated electrophoretically on NuPAGE® Bis-Tris 4-20 % gels and transferred to 
nitrocellulose membranes. Membranes were blocked (5% milk in TBS/0.05% Tween) before 
incubation overnight at 4°C with either purified anti-CCP2 IgG or FT IgG at a concentration 
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of 2 µg/ml in blocking buffer. Detection antibody (HRP-conjugated goat anti-human IgG) 
was added at a dilution of 1:10,000 in blocking buffer for 1 hour at RT, following detection 
using ECL chemiluminescence. 
 
3.8 IMMUNOHISTO- / IMMUNOCYTOCHEMISTRY 
In Study I, purified ACPAs were analyzed for binding to in vivo generated antigens using 
immunohisto- and immunocytochemistry. Briefly, synovial tissues from hip or knee biopsies 
were obtained from three RA patients undergoing joint replacement surgery. Snap frozen 
biopsies were cryostat sectioned, fixed with 2% formaldehyde, and stored at −80°C, before 
stained; SF mononuclear cells from three RA patients were isolated by ficoll separation, 
fixed in 2% formaldehyde, and stained. The SF ACPA IgG pool and corresponding FT IgG 
pool, described above, were biotinylated, before added at a concentration of 10µg/mL (on 
synovial tissues) or 5µg/mL (on SF mononuclear cells). Cells were permeabilized using 
PBS/saponine. Detection of bound antibodies was visualized using the vectastain detection 
system (on synovial tissues) or Streptavidin/HRP (on SF mononuclear cells).   
 
3.9 PEPTIDE ABSORPTION ASSAY 
In Study II, cross-reactivity between CEP-1 and carb-CEP-1 was determined through a 
peptide absorption assay. In brief, serum samples from CEP-1 single positive patients (n=4), 
carb-CEP-1 single positive patients (n=4) or CEP-1/carb-CEP-1 double positive patients were 
diluted 1:100 in RIA buffer and incubated with 100 µg/ml of either CEP-1 or carb-CEP-1 
peptide for 2 h at RT, before assayed for reactivity to CEP-1 or carb-CEP-1 using ELISA.  
  
3.10 B CELL CLONING 
3.10.1 B cell immortalization and cell culture 
In Paper IV, B cells were isolated from SF mononuclear cell samples (one RA patient and 
one non-RA disease control patient) via positive selection with CD22 Microbeads (Miltenyi 
Biotech). IgG-expressing memory B cells (CD19+CD27+IgM-IgA-) were subsequently 
isolated by flow cytometry on a FACSAria (Becton Dickinson); cells were then transduced 
with a retroviral vector expressing green fluorescent protein (GFP) marker, human Bcl-6 and 
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Bcl-xL, as previously described (134). GFP-positive clones were single-cell sorted by FACS 
into 96-well plates, expanded and maintained at a density of 2x105 cells/ml in expansion 
medium (IMDM + 8% FBS, penicillin/streptomycin and 25 mg/ml recombinant mouse IL-
21) in co-culture with γ-irradiated (50 Gy) mouse L-cell fibroblasts expressing human 
CD40L, plated at a density of 1x105 cells/ml. 
 
3.10.2 Antigen uptake assay 
In Paper IV, the ability of B cell clones to bind and internalize citrullinated fibrinogen was 
assessed using an antigen uptake assay. Human fibrinogen conjugated to Alexa-594 (Fib-594) 
was citrullinated according to the protocol described above. GFP-expressing B cell clones at 
a density of 1x105 cells/ml were then incubated with either unmodified (Fib-594) or 
citrullinated (cit-Fib-594) protein at a concentration of 1 µg/ml for 30 minutes at 4°C in PBS 
+ 10% FBS. Cells were then washed with PBS at RT, resuspended in VECTASHIELD 
mounting medium (Vector Labs) containing 4',6-diamidino-2-phenylindole (DAPI) for 
nuclear visualization, and transferred to glass slides for fluorescence microscopy using a 
Zeiss LSM710 Laser Scanning Microscope (Zeiss). 
 
3.11 STATISTICAL METHODS 
Differences in antibody levels (Study I, II and III), number of ACPA fine-specificities 
(Study II), DAS28 and CRP levels (Study III), between groups, were analyzed using Mann-
Whitney U test for independent groups. In Study II and III, odds ratios (OR) with 95% 
confidence intervals (CI) were calculated for associations between risk factors (i.e. smoking, 
HLA DRB1 SE and PTPN22 rs2476601) and different RA subsets. These analyses were 
performed in SAS version 9.3 (SAS Institute, Cary, NC, USA), and adjusted for age, gender 
and residential area. In Study III, co-occurrence of ACPA fine-specificities was calculated 
using Pearson correlation (R v. 3.3.3). For all statistical calculations, P-values <0.05 were 
considered significant.  
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3.12 ETHICAL CONSIDERATIONS 
The purpose of this PhD project - to gain a better understanding of the autoimmune reactions 
in RA - is aimed at benefiting patients. The project has involved patient material, and ethical 
considerations included protection of privacy and handling of personal data and biological 
material. All biological samples were collected with informed consent and ethical approval 
granted by the regional ethics review board at Karolinska Institutet, Stockholm, Sweden, or in 
the case for the patient from AMC in Study IV, from the medical ethical committee of AMC, 
Amsterdam, the Netherlands. Personal information has been handled under PUL, and kept 
behind the Karolinska University Hospital’s network firewall. Stored data does not include 
personal identifiers. All scientists and clinicians involved in the project have adhered to Good 
Clinical Practice / Good Laboratory Practice Guidelines. All studies were conducted in 
compliance with the Declaration of Helsinki: Ethical Principles for Medical Research 
Involving Human Subjects (135).
  23 
4  RESULTS AND DISCUSSION 
 
4.1 STUDY I 
While the CCP2 ELISA is commonly used for diagnosing ACPA-positive RA in the 
clinic, the CCP2 peptide (or peptides) itself is an artificial antigen whose sequence does not 
match any human proteins, and is therefore considered a surrogate marker for the true in vivo 
antigenic targets of ACPAs. Furthermore, whether or not the antibodies detected by the CCP2 
ELISA are the same that react with the numerous candidate citrullinated autoantigens 
identified in RA had never been explicitly demonstrated, with the exception of citrullinated 
fibrinogen (136). Therefore, in our first study, we set out to characterize the specificity of 
ACPAs detected by the CCP2 ELISA by isolating them from ACPA-positive RA patient 
samples through CCP2 affinity chromatography. Synovial fluid (n=26) and plasma (n=16) 
samples were collected from ACPA-positive RA patients with higher anti-CCP2 antibody 
levels (>300 AU/mL). Bulk IgG was first purified using Protein G columns, followed by 
isolation of anti-CCP2 IgG using an affinity column containing the CCP2 peptide, kindly 
donated by EuroDiagnostica AB. Flowthrough IgG (FT) from the CCP2 column was also 
saved and analyzed. 
We found that polyclonal ACPA IgG could be efficiently isolated using CCP2 
peptide affinity chromatography, and that these antibodies constitute approximately 2% of the 
total IgG pool, in both plasma and SF. The resulting CCP2 column eluates were found to bind 
a range of citrullinated peptide autoantigens in vitro using ELISA, as well as specifically 
binding to citrullinated (but not native) versions of human fibrinogen, vimentin and a-enolase 
proteins in Western blot. Conversely, the flowthrough fraction showed no binding in either 
ELISA or WB to either citrullinated or native peptides or proteins. Importantly, purified anti-
CCP2 IgG also bound in vivo targets in RA synovial tissue and on immune cells isolated from 
RA synovial fluid, whereas FT IgG did not (Figure 3). This could indicate a direct 
involvement of ACPAs in RA joint pathology. 
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Figure 3: Immunohisto-/immunochytochemistry demonstrating binding of purified and 
biotinylated ACPA IgG to antigens expressed in RA synovial tissue and SF mononuclear 
cells. There is no binding of FT IgG. Figure from Study I.  
 
Taken together, these results provide direct evidence that the autoantibodies measured 
by the CCP2 ELISA are the same ACPAs identified as binding to citrullinated peptide and 
protein antigens in vitro, and provide further evidence for the direct binding of ACPAs to 
antigens expressed in the inflamed joint. In addition, this study provided a large pool of 
polyclonal ACPA IgG for use in-house and in collaborations to study the characteristics and 
potential pathogenic effects of ACPA in a variety of in vitro and in vivo systems. The purified 
ACPAs have for example been used to demonstrate that the Fc-glycan profile of ACPAs 
differs from non-ACPA IgG, suggesting differences in effector and immunoregulatory 
functions (137). Moreover, the ACPA pool was shown to induce pain in an experimental 
animal model (104), and to active osteoclasts in vitro (103). Study I additionally provided 
the technical basis for the efficient affinity purification of ACPA IgG, something that was 
implemented in Study II. 
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4.2 STUDY II 
In addition to ACPAs and RF, antibodies to carbamylated proteins (anti-CarP 
antibodies) have been described in RA (106).  While originally described as a distinct RA-
specific autoantibody system, the biochemical similarity between citrulline and 
homocitrulline calls this into question, especially in light of the fact that purified ACPAs have 
been demonstrated to also bind carbamylated fibrinogen (114). Moreover, the presence of 
anti-CarP antibodies largely overlaps with ACPAs, which was demonstrated in both EIRA as 
well as the Dutch Early Arthritis Clinic (EAC) cohort (116). This led us to hypothesize that 
these antibodies were possibly no more than cross-reactive ACPAs. Prior to our study, the 
only protein that had been investigated in the context of anti-CarP reactivity was fibrinogen. 
Thus, we decided to focus on another candidate autoantigen in RA, α-enolase.  
Using a pool of anti-CCP2 IgG purified from 38 RA patients, in the same manner as in 
Study I, we were first able to demonstrate that anti-CCP2 IgG could bind both citrullinated 
and carbamylated (but not native) fibrinogen and α-enolase in Western blot (WB) (Figure 4).  
 
 
Figure 4: Western blot demonstrating binding of purified ACPA IgG to citrullinated and 
carbamylated a-enolase and fibrinogen. There is no binding to unmodified proteins, and no 
(or only weak/background) binding when blotting with FT IgG. Figure from Study II. 
 
 
proteins. The corresponding FT IgG pool bound neither
modified nor native proteins; only some weak unspecific
background staining was observed.
Purified anti-CEP-1 IgG displays cross-reactivity with a
homocitulline-containing version of CEP-1
To further investigate the specificity and extent of cross-
reactivity between citrullinated and carbamylated epitopes,
we focused on α-enolase and the immunodominant CEP-1
epitope. Affinity-purified anti-CEP-1-specific IgG bound
not only CEP-1 in ELISA, but also a version of CEP-1
(denoted carb-CEP-1) identical in sequence but with
citrulline residues replaced with homocitrullines. Anti-
CEP-1 IgG purified from different patients with RA showed
consistently strong binding to the CEP-1 peptide in ELISA
(data not shown), and in addition displayed varying de-
grees of binding to the carb-CEP-1 peptide (Fig. 1b).
Flow-through IgG from the same five patients did not
bind to CEP-1 or carb-CEP-1, demonstrating that the
carb-CEP-1 reactivity was confined to the anti-CEP-1
IgG eluate fraction. None of the anti-CEP-1 IgG column
eluates demonstrated reactivity to the control peptide
REP-1 (data not shown). Taken together, these data sug-
gest that citrullinated α-enolase-specific ACPA also have
the ability to bind homocitrulline-containing epitopes.
Anti-carb-CEP-1 reactivity in relation to anti-CEP-1 status
in EIRA
Using the large EIRA case-control cohort, we next sought
to determine the proportion of patients with RA with
antibodies binding to carb-CEP-1, and how this reactivity
correlated with CEP-1 positivity. Reactivity to CEP-1,
REP-1 and carb-CEP-1 was therefore analysed in serum
Fig. 1 Human anti-citrullinated protein antibodies (ACPA) cross-react with carbamylated epitopes. a Native (n), in vitro citrullinated (Cit) and in vitro
carbamylated (Carb) samples of recombinant human α-enolase and purified human fibrinogen were subjected to western blot using affinity-purified
nti-CCP2 IgG (ACPA IgG) a d CCP2-depleted column flow-through IgG (FT IgG), obtained from a pool of 38 rheumatoid arthritis (RA) serum samples.
b Affinity-purified anti-CEP-1 IgG and the corresponding column FT IgG fractions from five patients with RA were tested for reactivity to the carb-CEP-1
peptide in ELISA; antibody levels are presented as optical density (OD)
Fig. 2 Reactivity to CEP-1 and homocitrullinated CEP-1 peptide (carb-CEP-1) in Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA)
rheumatoid arthritis (RA) cases. a Sera from 2836 patients with RA from the EIRA cohort were tested for reactivity with CEP-1 and carb-CEP-1 using the
immuno solid-phase allergen chip multiplex assay (ISAC) platform and divided into subsets. b Anti-carb-CEP-1 antibody levels were compared between
the CEP-1+/carb-CEP-1+ and CEP-1-/carb-CEP-1+ subsets. Antibody levels are presented as arbitrary units (AU)
Reed et al. Arthritis Research & Therapy  (2016) 18:96 Page 4 of 9
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To investigate this crossreactivity in more detail, we then synthesized a “carbamylated” 
version of the immunodominant citrullinated α-enolase peptide epitope (CEP-1) - identical in 
sequence but with the citrullines replaced with homocitrullines - denoted carb-CEP-1. Sera 
from 2,836 EIRA patients and 373 EIRA controls were analysed for reactivity to CEP-1 and 
carb-CEP-1 in a high-throughput manner using the ISAC microarray. 41% of RA patients 
were found to be positive for anti-CEP-1 antibodies, in accordance with earlier data 
(131,138); the 21% of RA patients positive for anti-carb-CEP-1 antibodies were almost 
exclusively detected in the CEP-1-positive subset. Importantly, only 3% of patients were 
single positive for anti-carb-CEP-1 antibodies, and these patients had significantly lower anti-
carb-CEP-1 IgG levels than the double positive subset. Moreover, this subset was nearly 
eliminated (<1%) when the assay specificity was increased from 98% to 100%.  
In order to examine if the high co-occurrence of anti-CEP-1 and anti-carb-CEP-1 
antibodies was due to crossreactivity, we then performed peptide absorption experiments. 
Using sera from patients positive for either anti-CEP-1 antibodies only (n=4), anti-carb-CEP-
1 antibodies only (n=4), or both anti-CEP-1 and anti-carb-CEP-1 antibodies (n=4), we found 
crossreactivity to be consistently present, although at varying levels.  
To examine this cross-reactivity further, we purified anti-CEP-1 IgG from five CEP-1-
positive patients, using the same method as in Study I but with a CEP-1 column instead of 
CCP2. In ELISA, we found that purified anti-CEP-1 IgG showed strong and consistent 
binding to the CEP-1 peptide, but also varying degrees of binding to carb-CEP-1. FT IgG 
from the CEP-1 column did not bind to either peptide, indicating that antibodies binding to 
carb-CEP-1 were confined to the CEP-1 column eluate. These results clearly demonstrate that 
antibodies to citrullinated a-enolase also have the ability to bind to carbamylated epitopes. 
Positing that this cross-reactivity might be explained by the genetic or environmental 
basis of the disease, we also examined association with RA risk factors. Smoking and 
PTPN22 polymorphism showed no specific association with carb-CEP-1 positivity, in line 
with previous reports (116), while SE was significantly associated with both CEP-1 and carb-
CEP-1 positivity. The strength of the association was increased in double-positive patients 
compared to single-positive, indicating a SE-mediated effect on the development of cross-
reactive antibodies. Notably, we also observed an overall stronger ACPA response in the 
carb-CEP-1/CEP-1 double positive subset, compared to the CEP-1 single positive subset. 
Taken together, our data question the previous notion of anti-CarP antibodies as a 
separate autoantibody system in RA, and we propose that anti-CarP antibodies are cross-
reactive ACPAs. 
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4.3 STUDY III 
Most studies today are focused on trying to elucidate disease pathways in ACPA-
positive RA, where the autoantigen is known (at least to a certain extent), and where most 
known genetic and environmental risk factors seem to cluster. Much less is understood about 
the ACPA-negative subset of the disease. Using the commercially available anti-CCP2 
antibody assay frequently used in clinics, approximately 30% of RA patients will be 
considered ACPA-negative, and most of these patients will also be considered RF-negative. 
The lack of serological biomarkers presents an obstacle to prompt diagnosis for this group of 
patients. This subset comprises an intriguing complement to the “ACPA hypothesis” of RA 
pathogenesis: the relatively lower contribution of genetic and environmental risk factors 
important in ACPA-positive RA, combined with a relatively similar disease phenotype for 
both subsets suggests that disparate mechanisms in disease predisposition or initiation could 
lead to the development of a clinically similar disease. 
The overarching aim of Study III was to investigate how “seronegative” seronegative 
RA really is. We desired to confirm data from previous studies demonstrating that a subgroup 
of CCP2-negative RA patients have specific ACPAs that are not picked up by the CCP2 test 
(138,139). We also examined the frequency of IgM, IgG and IgA RF, since most RF tests 
used in the clinic identify primarily IgM RF. In addition, we analyzed a bank of non-RA-
related autoantibodies, including the anti-Ro/anti-La system, as the presence of non-RA-
related autoantibodies could potentially indicate possible disease misclassification in some 
cases. 
The basis for this study was a large serological dataset from the ISAC platform on the 
EIRA case-control cohort. Of the 2,836 RA sera examined, 989 were anti-CCP2 antibody 
negative, representing 35% of the whole EIRA RA population. Of these CCP2-negative RA 
patients, 67% were positive for at least one of the autoantibodies that we screened for; 34% 
were ACPA positive; 30% were RF positive; and 30% had antibodies to non-RA-related 
autoantigens. Cit-Fibb60-74 was the most common ACPA fine specificity among CCP2-
negative RA patients, with IgM RF as the most common RF isotype, and antibodies to the 
Ro/La antigens Ro60 and Ro52 as the most common non-RA-specific antibody.  
More ACPA fine-specificities and higher ACPA levels were detected in CCP2-positive 
RA, compared to CCP2-negative RA. All RF isotypes were also more frequent in the CCP2-
positive, compared to the CCP2-negative subset, while there was no such difference for other 
non-RA-specific autoantibodies. The co-occurrence of different ACPA, different RF isotypes, 
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and different antibody systems in general was more pronounced in CCP2-positive RA, 
compared to CCP2-negative RA (Figure 5). These findings suggest that there are at least two 
serologically distinct subsets of RA; and perhaps more importantly, that clinical screening for 
CCP2 and IgM RF clearly do not capture all “seropositive” RA patients.  
 
Figure 5: The distribution of ACPA, RF and other non-RA specific autoantibodies, among 
RA patients positive for at least one of these antibodies, in CCP2-positive and CCP2-negative 
subsets of EIRA. Figure from Study III. 
 
The different autoantibodies were subsequently analyzed in relation to CRP, DAS28 
and classical RA risk factors, in order to learn more about their potential role in RA etiology. 
These analyses showed only small differences in CRP levels and DAS28, indicating that 
presence/absence of these specific autoantibodies did not have a major impact on systemic 
inflammation or disease activity at the time of RA diagnosis, in line with what has been 
shown previously when comparing CCP2-positive and CCP2-negative early RA(140). 
Regarding HLA-DRB1 SE, we could confirm a previous report that SE associated with the 
presence of ACPA also in CCP2-negative RA, and in CCP2-positive RA we could 
demonstrate that the SE association was determined by six ACPA fine-specificities with high 
co-occurrence (or cross-reactivity). We could then show that presence of ACPA did not 
associate with smoking in CCP2-negative RA, but that presence of RF (and in particular IgA 
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RF) did, highlighting the importance of investigating ACPA in relation to RF when 
elucidating RA disease pathways. As shown previously, PTPN22 polymorphism, which has 
been linked to a number of autoimmune diseases as well as the presence of autoreactive B 
cells in systemically healthy individuals, seems to associate with RA, irrespective of ACPA 
and RF status (141,142). Interestingly, even when all autoantibodies were considered, the 
association with PTPN22 did not change significantly. The gene-environment and gene-gene 
interactions which are known to exist between SE and smoking (65) and between SE and 
PTPN22 (143) were not investigated in our study, but such analyses would add complexity to 
the interpretation of our findings. 
In summary, Study III supports the idea of RA as comprising at least two disease 
entities, possibly with disparate etiopathogenic mechanisms leading up to a similar clinical 
picture. Moreover, our study confirms that “seronegative” RA is not entirely a seronegative 
disease subset, and that additional screening for ACPA fine-specificities and RF isotypes 
could potentially help diagnose a substantial proportion of patients with RA at an earlier time 
point than is currently possible. This is of great importance, as earlier treatment in RA is 
beneficial regardless of serological status (144-146).  
 
4.4 STUDY IV 
Research on the ACPA response has largely focused on the antibodies themselves. 
However, much less is understood about the characteristics and potential pathogenic 
contribution of ACPA-producing B cells, despite the clear implication of B cells themselves 
in RA by the efficacy of rituximab. The major barrier to this line of inquiry has been the 
technical difficulty of maintaining or expanding B lymphocytes ex vivo without 
differentiation into plasmablasts, which lose their ability to present antigen to T cells.  
However, a recently published method allows the immortalization of B cells through the 
ectopic expression of Bcl-6 and Bcl-xL - regulators of B cell differentiation and apoptosis - 
which can then be expanded in the presence of CD40L and IL-21 without differentiation 
(134). These cells have been described as possessing a germinal center-like phenotype, with 
preserved costimulatory and antigen-presenting capacity. We utilized this method in Study 
IV to generate ACPA-producing B cell clones, in order to establish a platform for 
investigating the antigen specificity and functional characteristics of the ACPA B cell 
repertoire. 
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We first selected a SE-positive, CCP2-positive RA patient (denoted RA1003) with a 
high CCP2 titer, from which we isolated IgG-positive memory SF B cells 
(CD22+/CD19+/CD27+/IgM-/IgA-) using microbeads and flow cytometry. These memory B 
cells were then stimulated in the presence of CD40L and recombinant human IL-21 and 
subsequently immortalized by transduction with a retroviral vector expressing the 
transcription factors Bcl-6 and Bcl-xL, as well as GFP marker. Transduced GFP-expressing 
clones were then single-cell sorted into 96-well plates and expanded in the presence of 
CD40L and IL-21. We also derived B cell clones from SF of a non-RA, CCP2-negative 
disease control (denoted BB5327), in the same manner.   
Transduced B cell supernatants were assayed for ACPA reactivity using the CCP2 
ELISA. Of the 40 SF B-cell clones derived from RA1003, five tested positive for CCP2 
(12.5%); as expected, none of the 50 clones derived from BB5327 were positive in the CCP2 
ELISA. The proportion of ACPA-producing B cells derived from the RA patient is somewhat 
lower than previous reports for synovial B cells (25-40%) (128,147), but greatly increased 
when compared to the frequency in peripheral blood (approximately 1 in 12,500) (148), 
confirming the enrichment of SF B cells for ACPA positivity in seropositive RA.  
Next, we determined the ACPA fine-specificity of the CCP2-positive clones using the 
ISAC array containing citrullinated peptides, as in Study II and III. Only two of the five 
CCP2-positive clones (RA1003.3 and RA1003.4) produced IgG that bound citrullinated 
peptides on ISAC, with each of these clones binding strongly to CEP-1 and weakly to a 
citrullinated fibrinogen peptide (Cit-Fibb36-52). No binding was seen to the corresponding 
arginine-containing control peptides. Sequencing of the immunoglobuline sequence of the 
two CEP-1-positive clones revealed that they were in fact the same clone, expressing IgG1.  
As we wished to use this method to investigate the ability of ACPA B cells to present 
peptides from citrullinated proteins, we next determined the specificity of RA1003.3 to in 
vitro citrullinated or carbamylated α-enolase and fibrinogen in ELISA. RA1003.3 specifically 
bound citrullinated fibrinogen and carbamylated α-enolase. The lack of binding to 
citrullinated α-enolase despite strong binding to CEP-1 could be due to a lack of citrullination 
at the CEP-1 epitope, or a lack of accessibility of the CEP-1 epitope in ELISA. Finally, we 
proceeded to verify the ability of RA1003.3 to bind citrullinated fibrinogen on the cell 
surface. RA1003.3 cells were incubated with either unmodified or citrullinated fibrinogen 
coupled to Alexa-594, washed and subjected to confocal fluorescence microscopy. RA1003.3 
exhibited specific binding of citrullinated fibrinogen, and did not bind native fibrinogen 
(Figure 6). 
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Figure 6: Immortalized B cell clone RA1003.3 binds citrullinated fibrinogen (right panel), 
but not native fibrinogen (left panel). Green GFP indicates the cytoplasm; red Alexa-595 
shows fibrinogen; blue DAPI indicates the cell nuclei. Figure from Study IV. 
 
We have yet to demonstrate internalization, and that surface binding of citrullinated 
fibrinogen indeed is mediated by the B cell receptor. Still, our results confirm the utility of 
this method for deriving antigen-specific autoreactive B cells from patient material. It also 
supports our findings of cross-reactivity between ACPA and anti-CarP antibodies in Study 
II, as RA1003.3 was able to bind both citrullinated and carbamylated epitopes.  
  
 
 
 
Figure 3 
Specific binding of citrullinated fibrinogen by immortalized B cell clone RA1003.3. 
RA1003.3 clones expressing GFP in the cytoplasm (green) were incubated with either 
unmodified (A) or in vitro-citrullinated (B) human fibrinogen conjugated to Alexa-594 (red); 
nuclei were visualized by DAPI (blue); antigen-binding was evaluated by confocal 
microscopy. 
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5 CONCLUSIONS 
The main findings from the projects presented in this thesis are as follows: 
• The anti-CCP2 test detects ACPAs against a varity of in vitro citrullinated proteins 
and peptides, as well as antigens present in vivo in the rheumatoid joint (Study I). 
• Cross-reactivity is a common component of the ACPA response - between different 
citrullinated antigens, and between citrullinated and carbamylated (i.e. 
homocitrullinated) antigens (Studies II and IV). 
• In light of the cross-reactivity between citrullinated and carbamylated antigens, the 
existence of an independent anti-CarP antibody system is questionable (Study II).  
• Seronegative RA is not entirely a seronegative disease subset: ACPA and/or IgA RF 
and/or IgG RF are present in a proportion of CCP2-negative / IgM RF-negative 
patients, and this subset resembles seropositive RA in terms of associations with risk 
factors (Study III). 
• While HLA-DRB1 SE also associates with the presence of ACPA in CCP2-negative 
disease, smoking showed a significant association with RF, but not with ACPA, 
highlighting the importance of investigating ACPA together with RF when 
elucidating disease pathways in RA (Study III).  
• The ACPA-negative/RF-negative subset of RA still requires better biomarkers; no 
major association could be detected for autoantibodies present in other autoimmune 
diseases (Study III). 
• ACPA-producing B cell clones can be isolated and expanded from CCP2-positive RA 
patients, and are able to bind citrullinated proteins in vitro, providing a tool for the 
future investigation of the role of ACPA-producing B cells in RA (Study IV). 
Taken together, these results provide a basis for future investigation into the putative 
specificity and mechanism of the ACPA response. From Study I, it is clear that the CCP2 
assay comprehensively and directly captures the ACPA response. Work with purified ACPA 
IgG in Study I and II confirmed that cross-reactivity is likely a common component of the 
ACPA response. In particular, investigation of the crossreactivity of anti-CEP-1 antibodies 
with carbamylated epitopes in Study II suggests that the anti-CarP antibody response is far 
from discrete and may be a subset of ACPAs. The results of Study III further underline the 
serological differences between ACPA-positive and ACPA-negative RA and supports the 
idea that disease in ACPA-negative RA might arise through mechanisms disparate to ACPA-
positive RA. Finally, the results of Study IV provide a methodological basis for the 
mechanistic interrogation of ACPA-producing B-cells in RA. 
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6 FUTURE DIRECTIONS 
 
While the “ACPA hypothesis” of RA is intriguing, the lack of any definitive study 
supporting the pathogenicity of either human ACPAs or ACPA-specific lymphocytes is 
troubling. One possible explanation is that the ACPAs present in established disease may 
have lost their specificity and affinity due to epitope-spreading in the chronic inflammatory 
environment in the synovium. In this case, the isolation and characterization of ACPAs or 
ACPA lymphocytes present in the preclinical stage of the disease would be imperative to 
provide answers as to the true antigenic target of ACPAs (if one exists) as well as their ability 
to initiate disease. However, the fact that ACPAs in pre-clinical stages are present at such low 
levels, combined with the practical difficulty of prospectively recruiting pre-symptomatic 
individuals, makes this approach difficult. That said, a number of efforts are currently being 
made to recruit ACPA-positive individuals with arthralgia but before the onset of synovitis, 
in order to address precisely these questions.   
At least two published studies (149,150) have demonstrated that healthy individuals 
also commonly possess immature B cells in peripheral circulation capable of producing 
ACPAs upon activation (though they do not spontaneously secrete antibody in non-RA 
individuals). It has also been observed that non-RA B-cell lymphoma patients have 
significantly increased prevalence of ACPAs compared to healthy controls, albeit at low titres 
(151). It would seem likely then that control of B cell tolerance to (abnormally) citrullinated 
proteins is poorly regulated, and that the generation of ACPA-specific immature B cells is a 
common event. If so, this would underscore the importance of HLA-dependent T-cell help in 
the activation of these immature ACPA-positive B cells in RA. It would be interesting to 
explore the characteristics of these ACPA, either through isolation of B cell clones and/or 
molecular cloning of the immunoglobulin sequences from this "healthy" B cell population.  
However, there is also the possibility that ACPAs themselves are not pathogenic. 
Rather, they could be indicative of the immunological characteristics and/or anatomical 
location of inflammation in RA. Notably, low levels of ACPA are present in approximately 
2% of the general population (59), and the majority of these individuals will never develop 
RA. Moreover, while the transfer of ACPA to experimental animals can induce pain behavior 
and changes in bone structure, it does not seem to induce arthritis (103,104). Identifying the 
etiology of ACPAs would be crucial in elucidating their role in RA pathogenesis. Studies on 
pre-clinical serum samples have revealed that the ACPA response matures over time, with 
increased Ig levels, Ig usage, Fc glycosylation and epitope-spreading, before onset of clinical 
synovitis (63,152-154). However, no single ACPA fine-specificity have been identified as 
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being the first to appear, and no single ACPA fine-specificity have been shown to eventually 
cause arthritis. A broader approach to identify in vivo targets is therefore necessary. 
Additionally, while the use of peptide antigens derived from different candidate autoantigens 
is convenient for screening purposes, it is questionable if they have any relationship to in vivo 
B cell targets, as B cell epitopes are typically conformational, not linear.  
However, the findings of this thesis will hopefully allow these questions to be answered 
in the future. Through Study I, we have generated ACPA pools that are now being used for 
the identification of in vivo antigen targets, as well as effects on cell populations, as well as 
their capability to induce arthritis in animal models. Through Study II, we can confirm that 
ACPA cross-reacts with carbamylated antigens. This has now been shown for three candidate 
autoantigens in RA (i.e. fibrinogen (114), a-enolase and vimentin (118)), but whether this 
phenomenon has any relevance in vivo requires further investigation. Study III highlights the 
need for new biomarkers, better classification of seronegative RA, and better clinical tests for 
seropositive RA. And finally, the results in Study IV - while very preliminary - lay the 
ground for high-throughput, in-depth studies of the characteristics of the ACPA lymphocyte 
population, specifically in regards to HLA-DRB1 SE-mediated antigen presentation, and 
theoretically could even serve as a test bed for ACPA-specific therapeutics.  
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